Johnson and Johnson agreed to pay an estimated $5.5 billion to resolve roughly 76,000 lawsuits alleging its baby powder caused ovarian cancer, a deal that could finally close a decade-long legal saga that survived three failed bankruptcies and a federal judge’s skepticism of the plaintiffs’ core scientific evidence. The settlement covers nearly all remaining talc claims consolidated in federal court in New Jersey and related state cases, though it requires acceptance by 95 percent of claimants before it becomes final.
The bankruptcy detour failed
The agreement arrives after J&J spent more than three years pursuing a “Texas two-step” strategy, filing three successive bankruptcies through a shell subsidiary to force a global resolution. Each filing was dismissed. Litigation resumed in March 2025, and the company’s leverage shifted quickly: a federal judge last week cast doubt on individual plaintiffs’ ability to prove talc specifically caused their cancer, following earlier rulings that disqualified plaintiffs’ lawyers and struck expert testimony. J&J’s vice president of litigation, Erik Haas, called the claims “meritless” and said the company settled only to secure closure.
No cap on the final bill
The payment schedule is back-loaded: $3 billion is expected in 2027 with further installments in 2028. But the total is uncapped. Chris Seeger, an attorney representing about 2,500 claimants who helped negotiate the deal, said J&J could ultimately pay $7 billion or more depending on participation rates. The settlement assigns fixed values to qualifying ovarian cancer claims but sets no ceiling on aggregate liability, a structure that, unlike the rejected bankruptcy proposals, excludes future lawsuits entirely. That exclusion freed up more money for current plaintiffs and compresses the payout window to 18 months instead of a decade-plus.
What the market gets wrong
J&J stopped selling talc-based baby powder in the United States in 2020, switching to cornstarch, yet the litigation machine kept grinding. The company’s trial record was mixed before the bankruptcy pause: a multibillion-dollar verdict for 22 women, some defense wins, and appellate reductions. Now, with the scientific foundation of the remaining cases undermined by the court, J&J is paying billions to make claims it calls baseless go away. The logic is coldly rational, the cost of certainty is lower than the cost of continued uncertainty, but it is also a reminder that in mass torts, the price of exit rarely reflects the merits of the science.